Type I interferons in anticancer immunity

Nature Reviews Immunology

15, 405-414

DOI: 10.1038/nri3845

Citation Report

#	Article	IF	Citations
1	Manipulation of Innate Immunity for Cancer Therapy in Dogs. Veterinary Sciences, 2015, 2, 423-439.	0.6	17
2	Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Frontiers in Immunology, 2015, 6, 402.	2.2	135
3	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell, 2015, 28, 690-714.	7.7	1,205
4	Human consensus interferons: Bridging the natural and artificial cytokines with intrinsic disorder. Cytokine and Growth Factor Reviews, 2015, 26, 637-645.	3.2	6
5	Immune-modulators to combat hepatitis B virus infection: From IFN-Î± to novel investigational immunotherapeutic strategies. Antiviral Research, 2015, 122, 69-81.	1.9	56
6	Subversion of anticancer immunosurveillance by radiotherapy. Nature Immunology, 2015, 16, 1005-1007.	7.0	35
7	Interferon-Related Secretome Plays a Vital Role in PD-L1 Expression in the Tumor Microenvironment after Direct Interaction between Immune Cells and Tumor Cells. Single Cell Biology, 2016, 5, .	0.2	0
8	Design and evaluation of novel interferon lambda analogs with enhanced antiviral activity and improved drug attributes. Drug Design, Development and Therapy, 2016, 10, 163.	2.0	13
9	Trisomy 21 consistently activates the interferon response. ELife, 2016, 5, .	2.8	238
10	Interferon Î± Induces the Apoptosis of Cervical Cancer HeLa Cells by Activating both the Intrinsic Mitochondrial Pathway and Endoplasmic Reticulum Stress-Induced Pathway. International Journal of Molecular Sciences, 2016, 17, 1832.	1.8	18
11	Decreased Expression of TMEM173 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0165681.	1.1	45
12	pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8098-8103.	3.3	164
13	IFN Regulatory Factors and Antiviral Innate Immunity: How Viruses Can Get Better. Journal of Interferon and Cytokine Research, 2016, 36, 414-432.	0.5	18
14	Panâ€cancer analysis of copy number changes in programmed deathâ€ligand 1 (PDâ€L1, CD274) â€“ associations with gene expression, mutational load, and survival. Genes Chromosomes and Cancer, 2016, 55, 626-639.	1.5	80
15	The Interaction Between Human Papillomaviruses and the Stromal Microenvironment. Progress in Molecular Biology and Translational Science, 2016, 144, 169-238.	0.9	21
16	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
17	Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice. Neurosurgical Focus, 2016, 41, E4.	1.0	36
18	The immune network in thyroid cancer. OncoImmunology, 2016, 5, e1168556.	2.1	88

#	Article	IF	Citations
19	Beyond autophagy: New roles for ULK1 in immune signaling and interferon responses. Cytokine and Growth Factor Reviews, 2016, 29, 17-22.	3.2	19
20	STAT3 inhibition for cancer therapy: Cell-autonomous effects only?. OncoImmunology, 2016, 5, e1126063.	2.1	12
21	Emerging nanotechnologies for cancer immunotherapy. Experimental Biology and Medicine, 2016, 241, 1116-1126.	1.1	26
22	Transformable DNA nanocarriers for plasma membrane targeted delivery of cytokine. Biomaterials, 2016, 96, 1-10.	5.7	46
23	Rupestonic acid derivative YZH-106 suppresses influenza virus replication by activation of heme oxygenase-1-mediated interferon response. Free Radical Biology and Medicine, 2016, 96, 347-361.	1.3	42
24	2â€²-5â€² oligoadenylate synthetase-like 1 (OASL1) deficiency suppresses central nervous system damage in a murine MOG-induced multiple sclerosis model. Neuroscience Letters, 2016, 628, 78-84.	1.0	6
25	Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nature Reviews Immunology, 2016, 16, 741-750.	10.6	262
26	HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer. Journal of Virology, 2016, 90, 8984-8993.	1.5	47
27	Laser Therapy Inhibits Tumor Growth in Mice by Promoting Immune Surveillance and Vessel Normalization. EBioMedicine, 2016, 11, 165-172.	2.7	52
28	DAMPâ€”Induced Allograft and Tumor Rejection: The Circle Is Closing. American Journal of Transplantation, 2016, 16, 3322-3337.	2.6	61
29	Respiratory syncytial virus non-structural protein 1 facilitates virus replication through miR-29a-mediated inhibition of interferon-Î± receptor. Biochemical and Biophysical Research Communications, 2016, 478, 1436-1441.	1.0	25
30	Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood, 2016, 128, 680-685.	0.6	119
31	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. OncoImmunology, 2016, 5, e1214790.	2.1	64
32	cGASâ€cGAMPâ€STING: The three musketeers of cytosolic DNA sensing and signaling. IUBMB Life, 2016, 68, 858-870.	1.5	107
33	Ecrg4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling. OncoImmunology, 2016, 5, e1242547.	2.1	14
34	Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?. European Journal of Cancer, 2016, 68, 134-147.	1.3	103
35	Clinical significance of tumor-infiltrating lymphocytes in breast cancer. , 2016, 4, 59.		530
36	Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8 ⁺ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7240-E7249.	3.3	187

#	Article	IF	Citations
37	Expansion of amphibian intronless interferons revises the paradigm for interferon evolution and functional diversity. Scientific Reports, 2016, 6, 29072.	1.6	61
38	A quantum leap in cancer vaccines?. , 2016, 4, 87.		3
39	Rb selectively inhibits innate IFN-Î² production by enhancing deacetylation of IFN-Î² promoter through HDAC1 and HDAC8. Journal of Autoimmunity, 2016, 73, 42-53.	3.0	31
40	Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. Cancer Research, 2016, 76, 3122-3126.	0.4	47
41	Type 1 Interferons Induce Changes in Core Metabolism that Are Critical for Immune Function. Immunity, 2016, 44, 1325-1336.	6.6	248
42	Cytotoxic effects induced by interferon-ï‰ gene lipofection through ROS generation and mitochondrial membrane potential disruption in feline mammary carcinoma cells. Cytokine, 2016, 84, 47-55.	1.4	8
43	Plasmacytoid dendritic cell role in cutaneous malignancies. Journal of Dermatological Science, 2016, 83, 3-9.	1.0	30
44	Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 2016, 534, 396-401.	13.7	1,243
45	2â€²â€“5â€² Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons. Cancer Immunology, Immunotherapy, 2016, 65, 663-675.	2.0	12
46	Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes. JAMA Oncology, 2016, 2, 1354.	3.4	426
47	Trial Watchâ€”Immunostimulation with cytokines in cancer therapy. OncoImmunology, 2016, 5, e1115942.	2.1	52
48	HIV immunotherapy comes of age: implications for prevention, treatment and cure. Expert Review of Clinical Immunology, 2016, 12, 91-94.	1.3	10
49	Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. Cell Reports, 2016, 15, 171-180.	2.9	83
50	Vaccine adjuvants as potential cancer immunotherapeutics. International Immunology, 2016, 28, 329-338.	1.8	187
51	Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy. Immunology Letters, 2016, 178, 31-36.	1.1	39
52	Caspases Connect Cell-Death Signaling to Organismal Homeostasis. Immunity, 2016, 44, 221-231.	6.6	279
53	Trial Watchâ€”Oncolytic viruses and cancer therapy. OncoImmunology, 2016, 5, e1117740.	2.1	88
54	Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. OncoImmunology, 2016, 5, e1149673.	2.1	136

#	Article	IF	Citations
55	Trial Watchâ€"Small molecules targeting the immunological tumor microenvironment for cancer therapy. OncoImmunology, 2016, 5, e1149674.	2.1	46
56	First oncolytic virus approved for melanoma immunotherapy. OncoImmunology, 2016, 5, e1115641.	2.1	247
57	Combination cancer immunotherapies tailored to the tumour microenvironment. Nature Reviews Clinical Oncology, 2016, 13, 143-158.	12.5	753
58	Tyrosine kinase 2 â€“ Surveillant of tumours and bona fide oncogene. Cytokine, 2017, 89, 209-218.	1.4	45
59	Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. OncoImmunology, 2017, 6, e1163456.	2.1	30
60	Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells. OncoImmunology, 2017, 6, e1261240.	2.1	25
61	Heterogeneity in Immune Marker Expression afterÂAcquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell LungÂCancer Transformation. Journal of Thoracic Oncology, 2017, 12, 1015-1020.	0.5	20
62	The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. Clinical Epigenetics, 2017, 9, 4.	1.8	33
63	STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling. Nature Structural and Molecular Biology, 2017, 24, 279-289.	3.6	140
64	Dendritic cells in cancer: the role revisited. Current Opinion in Immunology, 2017, 45, 43-51.	2.4	339
65	JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. OncoImmunology, 2017, 6, e1291106.	2.1	119
66	IFNAR1 Degradation: A New Mechanism for Tumor Immune Evasion?. Cancer Cell, 2017, 31, 161-163.	7.7	20
67	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature Communications, 2017, 8, 14340.	5.8	110
68	Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell, 2017, 31, 194-207.	7.7	179
69	Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. OncoImmunology, 2017, 6, e1314424.	2.1	106
70	A STING-activating nanovaccine for cancer immunotherapy. Nature Nanotechnology, 2017, 12, 648-654.	15.6	649
71	Pro-necrotic molecules impact local immunosurveillance in human breast cancer. OncoImmunology, 2017, 6, e1299302.	2.1	88
72	Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8⁺T cells. OncoImmunology, 2017, 6, e1318234.	2.1	12

#	Article	IF	Citations
73	Epigenetics and immunotherapy: The current state of play. Molecular Immunology, 2017, 87, 227-239.	1.0	167
74	miRâ€2909 regulates ISGylation system via STAT1 signalling through negative regulation of SOCS3 in prostate cancer. Andrology, 2017, 5, 790-797.	1.9	17
75	3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells. Scientific Reports, 2017, 7, 1093.	1.6	130
76	The added value of type I interferons to cytotoxic treatments of cancer. Cytokine and Growth Factor Reviews, 2017, 36, 89-97.	3.2	25
77	Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199aâ€“LCOR axis. Nature Cell Biology, 2017, 19, 711-723.	4.6	83
78	Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-Î± Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. Cancer Research, 2017, 77, 4146-4157.	0.4	107
79	Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression. Cancer Immunology Research, 2017, 5, 560-570.	1.6	10
80	Reducing interferon'ce in stem cells. Nature Cell Biology, 2017, 19, 597-599.	4.6	0
81	Type I Interferon in Chronic Virus Infection and Cancer. Trends in Immunology, 2017, 38, 542-557.	2.9	344
82	The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation. Cell Communication and Signaling, 2017, 15, 13.	2.7	63
83	Src family kinases Fyn and Lyn are constitutively activated and mediate plasmacytoid dendritic cell responses. Nature Communications, 2017, 8, 14830.	5.8	30
84	Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents. International Review of Cell and Molecular Biology, 2017, 330, 115-156.	1.6	22
85	Post-nano strategies for drug delivery: multistage porous silicon microvectors. Journal of Materials Chemistry B, 2017, 5, 207-219.	2.9	47
86	Targeting cancerâ€related inflammation in the era of immunotherapy. Immunology and Cell Biology, 2017, 95, 325-332.	1.0	128
87	Necroptosis: Mechanisms and Relevance to Disease. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 103-130.	9.6	458
88	c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals. Blood, 2017, 130, 2739-2749.	0.6	8
89	Immune recognition of irradiated cancer cells. Immunological Reviews, 2017, 280, 220-230.	2.8	73
90	The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy. Science China Life Sciences, 2017, 60, 1058-1064.	2.3	19

#	Article	IF	Citations
91	6-Hydroxy-3- O -methyl-kaempferol 6- O -glucopyranoside potentiates the anti-proliferative effect of interferon Î±/Î² by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells. Toxicology and Applied Pharmacology, 2017, 336, 31-39.	1.3	19
92	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. Cell Reports, 2017, 20, 1818-1829.	2.9	220
93	Neoadjuvant Interferons: Critical for Effective PD-1â€“Based Immunotherapy in TNBC. Cancer Immunology Research, 2017, 5, 871-884.	1.6	63
94	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology, 2017, 6, e1371896.	2.1	36
95	Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology, 2017, 6, e1373237.	2.1	62
96	Role of cellular metabolism in regulating type I interferon responses: Implications for tumour immunology and treatment. Cancer Letters, 2017, 409, 20-29.	3.2	17
97	Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigenâ€“specific CTLs. Science Translational Medicine, 2017, 9, .	5.8	180
98	NEMOâ€“IKKÎ² Are Essential for IRF3 and NF-ÎºB Activation in the cGASâ€“STING Pathway. Journal of Immunology, 2017, 199, 3222-3233.	0.4	169
99	ATF3 negatively regulates cellular antiviral signaling and autophagy in the absence of type I interferons. Scientific Reports, 2017, 7, 8789.	1.6	25
100	Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms. Nature Communications, 2017, 8, 344.	5.8	61
101	Versican-Derived Matrikines Regulate Batf3â€“Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer. Journal of Immunology, 2017, 199, 1933-1941.	0.4	82
102	Blinatumomab bridges the gap between leukemia and immunity. OncoImmunology, 2017, 6, e1358335.	2.1	5
103	Control of Metastasis by NK Cells. Cancer Cell, 2017, 32, 135-154.	7.7	549
104	Extrachromosomal telomere repeat DNA is linked to ALT development via cGAS-STING DNA sensing pathway. Nature Structural and Molecular Biology, 2017, 24, 1124-1131.	3.6	103
105	TRAIL, Fas Ligand, TNF and TLR3 in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2017, , .	0.1	5
106	Immunosurveillance profile of oral squamous cell carcinoma and oral epithelial dysplasia through dendritic and Tâ€cell analysis. Journal of Oral Pathology and Medicine, 2017, 46, 928-933.	1.4	30
107	Identification of Interacting Stromal Axes in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 4673-4683.	0.4	25
108	Immunogenic cell death in cancer and infectious disease. Nature Reviews Immunology, 2017, 17, 97-111.	10.6	2,000

#	Article	IF	Citations
109	Negative regulation of type I <scp>IFN</scp> signaling by phosphorylation of <scp>STAT</scp> 2 on T387. EMBO Journal, 2017, 36, 202-212.	3.5	27
110	A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon. Clinical Cancer Research, 2017, 23, 2038-2049.	3.2	16
111	Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. Oncogene, 2017, 36, 585-592.	2.6	15
112	Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance. Cancer Letters, 2017, 386, 87-99.	3.2	21
113	Combining Type I Interferons and 5-Aza-2â€²-Deoxycitidine to Improve Anti-Tumor Response against Melanoma. Journal of Investigative Dermatology, 2017, 137, 159-169.	0.3	60
114	Essential role of HCMV deubiquitinase in promoting oncogenesis by targeting anti-viral innate immune signaling pathways. Cell Death and Disease, 2017, 8, e3078-e3078.	2.7	44
115	Interferon-Î± Promotes the Expression of Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma. Journal of Cancer, 2017, 8, 2384-2393.	1.2	18
116	TREX1 is a checkpoint for innate immune sensing of DNA damage that fosters cancer immune resistance. Emerging Topics in Life Sciences, 2017, 1, 509-515.	1.1	8
117	The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes. International Journal of Molecular Sciences, 2017, 18, 2227.	1.8	30
118	Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment. Frontiers in Endocrinology, 2017, 8, 232.	1.5	44
119	Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases. Frontiers in Immunology, 2017, 8, 294.	2.2	56
120	Type I Interferons and Natural Killer Cell Regulation in Cancer. Frontiers in Immunology, 2017, 8, 304.	2.2	113
121	Getting â€œInsideâ€•Type I IFNs: Type I IFNs in Intracellular Bacterial Infections. Journal of Immunology Research, 2017, 2017, 1-17.	0.9	27
122	Beyond Immune Cell Migration: The Emerging Role of the Sphingosine-1-phosphate Receptor S1PR4 as a Modulator of Innate Immune Cell Activation. Mediators of Inflammation, 2017, 2017, 1-12.	1.4	46
123	Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight, 2017, 2, .	2.3	203
124	Interferons: Cellular and Molecular Biology of Their Actions â†. , 2017, , 286-286.		3
125	Inhibition of Proteasome Activity Induces Aggregation of IFIT2 in the Centrosome and Enhances IFIT2-Induced Cell Apoptosis. International Journal of Biological Sciences, 2017, 13, 383-390.	2.6	23
126	Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of Melanoma. PLoS ONE, 2017, 12, e0170025.	1.1	12

#	Article	IF	Citations
127	Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget, 2017, 8, 71249-71284.	0.8	138
128	Interferons. , 2017, , 51-70.		1
129	Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines, 2017, 5, 3.	1.4	29
130	Dietary quercetin potentiates the antiproliferative effect of interferon-Î± in hepatocellular carcinoma cells through activation of JAK/STAT pathway signaling by inhibition of SHP2 phosphatase. Oncotarget, 2017, 8, 113734-113748.	0.8	36
131	Prophylactic Vaccines for Nonviral Cancers. Annual Review of Cancer Biology, 2018, 2, 195-211.	2.3	8
132	Heating it up: Oncolytic viruses make tumors â€˜hotâ€™ and suitable for checkpoint blockade immunotherapies. OncoImmunology, 2018, 7, e1442169.	2.1	85
133	Anticancer Mechanisms in Two Murine Bone Marrowâ€“Derived Dendritic Cell Subsets Activated with TLR4 Agonists. Journal of Immunology, 2018, 200, 2656-2669.	0.4	8
134	Tollâ€like receptor 3 signal augments radiationâ€induced tumor growth retardation in a murine model. Cancer Science, 2018, 109, 956-965.	1.7	26
135	Self-Renewal and Toll-like Receptor Signaling Sustain Exhausted Plasmacytoid Dendritic Cells during Chronic Viral Infection. Immunity, 2018, 48, 730-744.e5.	6.6	39
136	<scp>RNA</scp> sensor <scp>LGP</scp> 2 inhibits <scp>TRAF</scp> ubiquitin ligase to negatively regulate innate immune signaling. EMBO Reports, 2018, 19, .	2.0	42
137	Breaking self-tolerance during autoimmunity and cancer immunity: Myeloid cells and type I IFN response regulation. Journal of Leukocyte Biology, 2018, 103, 1117-1129.	1.5	11
138	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. OncoImmunology, 2018, 7, e1433982.	2.1	38
139	Functional, signalling and transcriptional differences of three distinct type I IFNs in a perciform fish, the mandarin fish Siniperca chuatsi. Developmental and Comparative Immunology, 2018, 84, 94-108.	1.0	47
140	Environmentally Triggerable Retinoic Acid-Inducible Gene I Agonists Using Synthetic Polymer Overhangs. Bioconjugate Chemistry, 2018, 29, 742-747.	1.8	13
141	Activation of human CD141⁺ and CD1c⁺ dendritic cells in vivo with combined TLR3 and TLR7/8 ligation. Immunology and Cell Biology, 2018, 96, 390-400.	1.0	33
142	Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, 065-080.	0.4	26
143	NF-ÎºB, inflammation, immunity and cancer: coming of age. Nature Reviews Immunology, 2018, 18, 309-324.	10.6	1,796
144	Negative regulation of type I IFN signaling. Journal of Leukocyte Biology, 2018, 103, 1099-1116.	1.5	75

#	Article	IF	Citations
145	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	5.0	4,036
146	Module Analysis Captures Pancancer Genetically and Epigenetically Deregulated Cancer Driver Genes for Smoking and Antiviral Response. EBioMedicine, 2018, 27, 156-166.	2.7	40
147	From Local to Systemic Treatment: Leveraging Antitumor Immunity Following Irreversible Electroporation. , 2018, , 249-270.		4
148	Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. Seminars in Cancer Biology, 2018, 52, 125-134.	4.3	51
149	Innate Immune Receptors in the Regulation of Tumor Immunity. , 2018, , 407-427.		0
150	Challenges of Oncoimmunology for Ovarian and Breast Cancers. , 2018, , 607-619.		0
151	Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment. Journal of Immunology, 2018, 200, 1110-1123.	0.4	12
152	Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies. Trends in Immunology, 2018, 39, 209-221.	2.9	153
153	Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies. Journal of Immunology, 2018, 200, 450-458.	0.4	78
154	Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Science Translational Medicine, 2018, 10, .	5.8	242
155	HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment. Seminars in Oncology, 2018, 45, 27-33.	0.8	18
156	Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells. Cancer Cell, 2018, 33, 862-873.e5.	7.7	133
157	Interferon regulatory factor 1 inactivation in human cancer. Bioscience Reports, 2018, 38, .	1.1	75
158	SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17ÂCytokineÂProfile. Journal of Investigative Dermatology, 2018, 138, 1795-1804.	0.3	25
159	Standing in the GAP : To formulate a novel radioimmunotherapy regime to improve the long-term outcome in breast cancer. Immunotherapy, 2018, 10, 255-263.	1.0	2
160	Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist. Biomaterials, 2018, 178, 643-651.	5.7	49
161	IRF8 Regulates Transcription of Naips for NLRC4 Inflammasome Activation. Cell, 2018, 173, 920-933.e13.	13.5	142
162	A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. British Journal of Cancer, 2018, 118, 1035-1041.	2.9	77

#	Article	IF	Citations
163	An origin of the immunogenicity of in vitro transcribed RNA. Nucleic Acids Research, 2018, 46, 5239-5249.	6.5	123
164	Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia. Leukemia and Lymphoma, 2018, 59, 171-177.	0.6	1
165	Adipose type I interferon signalling protects against metabolic dysfunction. Gut, 2018, 67, 157-165.	6.1	61
166	Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers. Clinical Cancer Research, 2018, 24, 259-265.	3.2	137
168	Dual requirement for STAT signaling in dendritic cell immunobiology. Immunobiology, 2018, 223, 342-347.	0.8	8
169	Type I IFN Receptor Signaling Controls IL7-Dependent Accumulation and Activity of Protumoral IL17A-Producing Î³Î´T Cells in Breast Cancer. Cancer Research, 2018, 78, 195-204.	0.4	31
170	The Interferon (IFN) Class of Cytokines and the IFN Regulatory Factor (IRF) Transcription Factor Family. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028423.	2.3	251
171	Innate sensing of cancer's non-immunologic hallmarks. Current Opinion in Immunology, 2018, 50, 1-8.	2.4	9
172	DEAE-Dextran coated paclitaxel nanoparticles act as multifunctional nano system for intranuclear delivery to triple negative breast cancer through VEGF and NOTCH1 inhibition. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 122, 37-48.	2.0	14
173	Self-dsDNA in the pathogenesis of systemic lupus erythematosus. Clinical and Experimental Immunology, 2017, 191, 1-10.	1.1	76
174	cGASâ€“STING and Cancer: Dichotomous Roles in Tumor Immunity and Development. Trends in Immunology, 2018, 39, 44-54.	2.9	174
175	Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner. Biochemical and Biophysical Research Communications, 2018, 495, 1233-1239.	1.0	13
176	Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. Cancer Research, 2018, 78, 463-474.	0.4	70
177	Targeting the IDO1/TDO2â€“KYNâ€“AhR Pathway for Cancer Immunotherapy â€“ Challenges and Opportunities. Trends in Pharmacological Sciences, 2018, 39, 307-325.	4.0	278
178	Metabolic Endotoxemia-Activated Macrophages Promote Pancreatic Î² Cell Death via IFNÎ²-Xaf1 Pathway. Hormone and Metabolic Research, 2018, 50, 160-167.	0.7	10
179	A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. OncoImmunology, 2018, 7, e1398876.	2.1	44
180	Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. Journal of Clinical Oncology, 2018, 36, 3450-3458.	0.8	55
181	Direct Antiviral Mechanisms of Interferon-Gamma. Immune Network, 2018, 18, e33.	1.6	187

#	Article	IF	Citations
182	Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer. Breast Cancer Research, 2018, 20, 145.	2.2	18
183	Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. Oncotarget, 2018, 9, 7949-7960.	0.8	49
184	Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?. Frontiers in Immunology, 2018, 9, 2804.	2.2	94
185	Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer. Clinics, 2018, 73, e479s.	0.6	7
186	Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend. Frontiers in Immunology, 2018, 9, 2909.	2.2	183
187	Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. Cancer Management and Research, 2018, Volume 10, 6457-6468.	0.9	23
188	Activation of viral defense signaling in cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879310.	1.4	14
189	The intracellular signalosome of PD-L1 in cancer cells. Signal Transduction and Targeted Therapy, 2018, 3, 26.	7.1	174
190	Nanoparticleâ€Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses. Advanced Materials, 2018, 30, e1803397.	11.1	120
191	Cellular Inflammatory Responses. , 2018, , 475-590.		0
192	Linking cellular stress responses to systemic homeostasis. Nature Reviews Molecular Cell Biology, 2018, 19, 731-745.	16.1	320
193	Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals. Cell Death and Disease, 2018, 9, 1086.	2.7	20
194	Novel therapeutic strategies for advanced ovarian cancer by using induced pluripotent stem cellâ€derived myelomonocytic cells producing interferon beta. Cancer Science, 2018, 109, 3403-3410.	1.7	15
195	An isoform of AIF1 involved in breast cancer. Cancer Cell International, 2018, 18, 167.	1.8	10
196	Trial Watch: Toll-like receptor agonists in cancer immunotherapy. OncoImmunology, 2018, 7, e1526250.	2.1	172
197	Prologue: About DAMPs, PAMPs, and MAMPs. , 2018, , 191-217.		1
198	Transcriptional and chromatin regulation in interferon and innate antiviral gene expression. Cytokine and Growth Factor Reviews, 2018, 44, 11-17.	3.2	44
199	Immunoengineering through cancer vaccines â€“ A personalized and multi-step vaccine approach towards precise cancer immunity. Journal of Controlled Release, 2018, 289, 125-145.	4.8	31

#	Article	IF	Citations
200	Trial watch: Peptide-based vaccines in anticancer therapy. OncoImmunology, 2018, 7, e1511506.	2.1	121
201	STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia. Cell Reports, 2018, 24, 3045-3060.e5.	2.9	20
202	Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance. Frontiers in Oncology, 2018, 8, 322.	1.3	137
203	Ribonucleotide Excision Repair Is Essential to Prevent Squamous Cell Carcinoma of the Skin. Cancer Research, 2018, 78, 5917-5926.	0.4	40
204	Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. Clinical Cancer Research, 2018, 24, 4242-4255.	3.2	114
205	Regulation of interferon signaling and HCVâ€'RNA replication by extracellular matrix. International Journal of Molecular Medicine, 2018, 42, 957-965.	1.8	6
206	Plasmacytoid dendritic cell in immunity and cancer. Journal of Neuroimmunology, 2018, 322, 63-73.	1.1	117
207	Immune suppression and reversal of the suppressive tumor microenvironment. International Immunology, 2018, 30, 445-455.	1.8	110
208	Cytosolic DNA Sensing in Organismal Tumor Control. Cancer Cell, 2018, 34, 361-378.	7.7	191
209	Novel chemical compound <scp>SINCRO</scp> with dual function in <scp>STING</scp>â€type I interferon and tumor cell death pathways. Cancer Science, 2018, 109, 2687-2696.	1.7	8
210	Polymerization Induced Self-Assembly of a Site-Specific Interferon Î±-Block Copolymer Conjugate into Micelles with Remarkably Enhanced Pharmacology. Journal of the American Chemical Society, 2018, 140, 10435-10438.	6.6	71
211	STAT3/p53 pathway activation disrupts IFN-Î²â€"induced dormancy in tumor-repopulating cells. Journal of Clinical Investigation, 2018, 128, 1057-1073.	3.9	86
212	Antitumor Activity of Extract From the Sporoderm-Breaking Spore of Ganoderma lucidum: Restoration on Exhausted Cytotoxic T Cell With Gut Microbiota Remodeling. Frontiers in Immunology, 2018, 9, 1765.	2.2	70
213	Origin and Consequences of Necroinflammation. Physiological Reviews, 2018, 98, 727-780.	13.1	147
214	TLR-3 Stimulation Skews M2 Macrophages to M1 Through IFN-Î±Î² Signaling and Restricts Tumor Progression. Frontiers in Immunology, 2018, 9, 1650.	2.2	110
215	DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells. Theranostics, 2018, 8, 3198-3213.	4.6	18
216	Type I Interferon Signaling Is Required for CpG-Oligodesoxynucleotide-Induced Control of Leishmania major, but Not for Spontaneous Cure of Subcutaneous Primary or Secondary L. major Infection. Frontiers in Immunology, 2018, 9, 79.	2.2	25
217	Perturbation of Intracellular Cholesterol and Fatty Acid Homeostasis During Flavivirus Infections. Frontiers in Immunology, 2018, 9, 1276.	2.2	42

#	Article	IF	Citations
218	Î²â€catenin regulates IRF3â€mediated innate immune signalling in colorectal cancer. Cell Proliferation, 2018, 51, e12464.	2.4	17
219	DNA Tumor Virus Regulation of Host DNA Methylation and Its Implications for Immune Evasion and Oncogenesis. Viruses, 2018, 10, 82.	1.5	82
220	Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells. Journal of Virology, 2018, 92, .	1.5	35
221	STING signaling: a key to therapeutic tumor immunity. Immunotherapy, 2018, 10, 729-731.	1.0	2
222	Radiation-Induced Chromosomal Aberrations and Immunotherapy: Micronuclei, Cytosolic DNA, and Interferon-Production Pathway. Frontiers in Oncology, 2018, 8, 192.	1.3	96
223	Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy. EBioMedicine, 2018, 31, 17-24.	2.7	115
224	IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells. Journal of Immunology, 2018, 201, 264-277.	0.4	69
225	Non-canonical NF-Î¹B Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy. Immunity, 2018, 49, 490-503.e4.	6.6	155
226	Histone H2A.Z Suppression of Interferon-Stimulated Transcription and Antiviral Immunity Is Modulated by GCN5 and BRD2. IScience, 2018, 6, 68-82.	1.9	34
227	Cytokineâ€Functionalized Synthetic Dendritic Cells for TÂCell Targeted Immunotherapies. Advanced Therapeutics, 2018, 1, 1800021.	1.6	25
228	MiR-221 negatively regulates innate anti-viral response. PLoS ONE, 2018, 13, e0200385.	1.1	19
229	Losses of cytokines and chemokines are common genetic features of human cancers: the somatic copy number alterations are correlated with patient prognoses and therapeutic resistance. OncoImmunology, 2018, 7, e1468951.	2.1	7
230	Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha. Journal of Interferon and Cytokine Research, 2018, 38, 239-254.	0.5	9
231	Contribution of annexin A1 to anticancer immunosurveillance. OncoImmunology, 2019, 8, e1647760.	2.1	27
232	Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties. Journal of Virology, 2019, 93, .	1.5	58
233	Potent Lymphatic Translocation and Spatial Control Over Innate Immune Activation by Polymerâ€“Lipid Amphiphile Conjugates of Smallâ€Molecule TLR7/8 Agonists. Angewandte Chemie - International Edition, 2019, 58, 15390-15395.	7.2	43
234	Amphiphile Polymerâ€Lipidkonjugate zur potenten lymphatischen Anreicherung von TLR7/8â€Agonisten ermÃ¶glichen eine Ã¶rtlich begrenzte Aktivierung des angeborenen Immunsystems. Angewandte Chemie, 2019, 131, 15535-15541.	1.6	5
235	Cancer therapy with major histocompatibility complexâ€deficient and interferon Î²â€producing myeloid cells derived from allogeneic embryonic stem cells. Cancer Science, 2019, 110, 3027-3037.	1.7	8

#	Article	IF	Citations
236	MEK1/2 Inhibitors Unlock the Constrained Interferon Response in Macrophages Through IRF1 Signaling. Frontiers in Immunology, 2019, 10, 2020.	2.2	11
237	The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. International Journal of Molecular Sciences, 2019, 20, 3934.	1.8	69
238	Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. Frontiers in Immunology, 2019, 10, 1848.	2.2	56
239	Human Tumor-Infiltrating Dendritic Cells: From in Situ Visualization to High-Dimensional Analyses. Cancers, 2019, 11, 1082.	1.7	36
240	Development and validation of an interferon signature predicting prognosis and treatment response for glioblastoma. OncoImmunology, 2019, 8, e1621677.	2.1	30
241	NF-Î¹B/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB. Cancers, 2019, 11, 937.	1.7	36
242	NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. Nature Communications, 2019, 10, 3251.	5.8	55
243	Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy. ACS Nano, 2019, 13, 12671-12686.	7.3	86
244	The Role of Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio in Predicting Neoadjuvant Chemotherapy Response in Breast Cancer. Journal of Breast Cancer, 2019, 22, 425.	0.8	27
245	Three decades of messenger RNA vaccine development. Nano Today, 2019, 28, 100766.	6.2	177
246	Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses. Journal of Experimental Medicine, 2019, 216, 2854-2868.	4.2	49
247	Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances. Molecular Therapy - Oncolytics, 2019, 15, 234-247.	2.0	178
248	STING activation in cancer immunotherapy. Theranostics, 2019, 9, 7759-7771.	4.6	150
249	Autophagy Regulation of Innate Immunity. Advances in Experimental Medicine and Biology, 2019, , .	0.8	3
250	In vitro Effect of Recombinant Feline Interferon-Î© (rFeIFN-Î©) on the Primary CanineTransmissible Venereal Tumor Culture. Frontiers in Veterinary Science, 2019, 6, 104.	0.9	1
251	STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity. Cancer Immunology Research, 2019, 7, 1837-1848.	1.6	59
252	Distinct evolution of toll-like receptor signaling pathway genes in cetaceans. Genes and Genomics, 2019, 41, 1417-1430.	0.5	6
253	RIG-I activation is critical for responsiveness to checkpoint blockade. Science Immunology, 2019, 4, .	5.6	80

#	Article	IF	Citations
254	Prospects for combining immune checkpoint blockade with PARP inhibition. Journal of Hematology and Oncology, 2019, 12, 98.	6.9	92
255	Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells. Cell Reports, 2019, 29, 162-175.e9.	2.9	26
256	The correlation of BER protein, IRF3 with CD8+ T cell and their prognostic significance in upper tract urothelial carcinoma . OncoTargets and Therapy, 2019, Volume 12, 7725-7735.	1.0	16
257	Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy. International Journal of Pharmaceutics, 2019, 571, 118706.	2.6	30
258	Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas. OncoImmunology, 2019, 8, e1660121.	2.1	4
259	Delivery of 5â€²-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy. Biomaterials Science, 2019, 7, 547-559.	2.6	49
260	The EF-Hand Protein CALML6 Suppresses Antiviral Innate Immunity by Impairing IRF3 Dimerization. Cell Reports, 2019, 26, 1273-1285.e5.	2.9	14
261	Interferons Î± and Î² in cancer: therapeutic opportunities from new insights. Nature Reviews Drug Discovery, 2019, 18, 219-234.	21.5	258
262	Cancer Exosomes as Conveyors of Stress-Induced Molecules: New Players in the Modulation of NK Cell Response. International Journal of Molecular Sciences, 2019, 20, 611.	1.8	34
263	One-month zero-order sustained release and tumor eradication after a single subcutaneous injection of interferon alpha fused with a body-temperature-responsive polypeptide. Biomaterials Science, 2019, 7, 104-112.	2.6	19
264	Activation of the ILT7 receptor and plasmacytoid dendritic cell responses are governed by structurally-distinct BST2 determinants. Journal of Biological Chemistry, 2019, 294, 10503-10518.	1.6	8
265	Type I interferons and dendritic cells in cancer immunotherapy. International Review of Cell and Molecular Biology, 2019, 348, 217-262.	1.6	81
266	Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes. , 2019, 7, 157.		85
267	Craniopharyngioma: Current Classification, Management, and Future Directions. , 2019, , 561-583.		0
268	Oncolytic Activity of the Vaccine Strain of Type 3 Poliovirus on the Model of Rat Glioma C6 Cells. Bulletin of Experimental Biology and Medicine, 2019, 167, 111-115.	0.3	2
269	Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives. American Journal of Clinical Dermatology, 2019, 20, 817-827.	3.3	29
270	Evaluation of a single amino acid substitution at position 79 of human IFN-Î±2b in interferon-receptor assembly and activity. Preparative Biochemistry and Biotechnology, 2019, 49, 735-743.	1.0	0
271	Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS. Cell, 2019, 178, 176-189.e15.	13.5	327

#	Article	IF	Citations
272	Thermoresponsive and Proteaseâ€Cleavable Interferonâ€Polypeptide Conjugates with Spatiotemporally Programmed Twoâ€Step Release Kinetics for Tumor Therapy. Advanced Science, 2019, 6, 1900586.	5.6	23
273	Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Scientific Reports, 2019, 9, 8572.	1.6	36
274	Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Cancer Research, 2019, 79, 3940-3951.	0.4	154
275	Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response. OncoImmunology, 2019, 8, e1601480.	2.1	18
276	Immunology of Plasmacytoid Dendritic Cells in Solid Tumors: A Brief Review. Cancers, 2019, 11, 470.	1.7	63
277	Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia, 2019, 33, 2466-2480.	3.3	66
278	Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nature Cell Biology, 2019, 21, 511-521.	4.6	121
279	Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis. Journal of Neuroinflammation, 2019, 16, 53.	3.1	446
280	Nucleic Acid Sensing at the Interface Between Innate and Adaptive Immunity. International Review of Cell and Molecular Biology, 2019, 345, ix-xiii.	1.6	1
281	Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses. Stem Cells, 2019, 37, 716-723.	1.4	25
282	Dendritic Cells and Cancer: From Biology to Therapeutic Intervention. Cancers, 2019, 11, 521.	1.7	100
283	Enhanced Antitumor Immune Response in 2â€²-5â€² Oligoadenylate Synthetase-Like 1- (OASL1-) Deficient Mice upon Cisplatin Chemotherapy and Radiotherapy. Journal of Immunology Research, 2019, 2019, 1-14.	0.9	3
284	Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc+ Monocytes in Rectal Cancer. Frontiers in Immunology, 2019, 10, 602.	2.2	8
285	Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer. Journal of Immunology, 2019, 202, 3076-3086.	0.4	29
286	Nucleic Acid Sensing at the Interface Between Innate and Adaptive Immunity. International Review of Cell and Molecular Biology, 2019, 344, xi-xv.	1.6	3
287	Sustained Type I Interferon Reinforces NK Cellâ€“Mediated Cancer Immunosurveillance during Chronic Virus Infection. Cancer Immunology Research, 2019, 7, 584-599.	1.6	27
288	Effect of platinumâ€‘based chemotherapy on the expression of natural killer groupï¿½2 memberï¿½D ligands, programmed cell deathâ€‘1 ligandï¿½1 and HLA classï¿½I in nonâ€‘small cell lung cancer. Oncology Reports, 2019, 42, 839-848.	1.2	10
289	Advances and perspectives of PARP inhibitors. Experimental Hematology and Oncology, 2019, 8, 29.	2.0	81

#	Article	IF	Citations
290	Prefaceâ€”Dendritic cells: Master regulators of innate and adaptive immunity. International Review of Cell and Molecular Biology, 2019, 348, ix-xiv.	1.6	2
291	Preface: Dendritic cells: Master regulators of innate and adaptive immunity. International Review of Cell and Molecular Biology, 2019, 349, xi-xvi.	1.6	1
292	Harnessing innate immunity in cancer therapy. Nature, 2019, 574, 45-56.	13.7	533
293	NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2. Journal of Experimental and Clinical Cancer Research, 2019, 38, 483.	3.5	37
294	Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles. Nature Reviews Cardiology, 2019, 16, 33-55.	6.1	188
295	A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis. Molecular Cancer Research, 2019, 17, 109-119.	1.5	28
296	Concomitant type I IFN and M-CSF signaling reprograms monocyte differentiation and drives pro-tumoral arginase production. EBioMedicine, 2019, 39, 132-144.	2.7	15
297	Immune mechanisms mediating abscopal effects in radioimmunotherapy. , 2019, 196, 195-203.		52
298	Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nature Medicine, 2019, 25, 95-102.	15.2	240
299	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nature Reviews Drug Discovery, 2019, 18, 197-218.	21.5	2,005
300	Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome. Cancer Immunology Research, 2019, 7, 12-28.	1.6	21
301	Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma. Journal of Molecular Medicine, 2019, 97, 77-88.	1.7	14
302	Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies. Cytokine, 2019, 113, 446-452.	1.4	51
303	Evaluation of Newcastle disease virus mediated dendritic cell activation and crossâ€priming tumorâ€specific immune responses ex vivo. International Journal of Cancer, 2020, 146, 531-541.	2.3	9
304	Oncolysis without viruses â€” inducing systemic anticancer immune responses with local therapies. Nature Reviews Clinical Oncology, 2020, 17, 49-64.	12.5	92
305	Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cellular and Molecular Immunology, 2020, 17, 1-12.	4.8	273
306	Harnessing radiation to improve immunotherapy: better with particles?. British Journal of Radiology, 2020, 93, 20190224.	1.0	53
307	Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes. Clinical Cancer Research, 2020, 26, 505-517.	3.2	26

#	Article	IF	Citations
308	Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists. Journal of Medicinal Chemistry, 2020, 63, 260-282.	2.9	39
309	A Nanoparticle Platform for Improved Potency, Stability, and Adjuvanticity of Poly(I:C). Advanced Therapeutics, 2020, 3, 1900174.	1.6	13
310	Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models. Cancer Letters, 2020, 470, 170-180.	3.2	57
311	Type I interferons and endoplasmic reticulum stress in health and disease. International Review of Cell and Molecular Biology, 2020, 350, 63-118.	1.6	53
312	DNA Damage Response and Oxidative Stress in Systemic Autoimmunity. International Journal of Molecular Sciences, 2020, 21, 55.	1.8	68
313	Interferon-Î± inducible protein 6 (IFI6) confers protection against ionizing radiation in skin cells. Journal of Dermatological Science, 2020, 100, 139-147.	1.0	13
314	Infection and cancer suppress pDC derived IFN-I. Current Opinion in Immunology, 2020, 66, 114-122.	2.4	16
315	DNA Damage and Cancer Immunotherapy: A STING in the Tale. Molecular Cell, 2020, 80, 21-28.	4.5	161
316	Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results. Current Opinion in Oncology, 2020, 32, 585-593.	1.1	3
317	High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy. Cancers, 2020, 12, 2966.	1.7	16
318	Vertical transmission of hepatitis E virus in pregnant rhesus macaques. Scientific Reports, 2020, 10, 17517.	1.6	20
319	Royal Jelly and Human Interferon-Alpha (HuIFN-Î±N3) Affect Proliferation, Glutathione Level, and Lipid Peroxidation in Human Colorectal Adenocarcinoma Cells In Vitro. , 0, , .		0
320	The Relationship Between Protein S-Nitrosylation and Human Diseases: A Review. Neurochemical Research, 2020, 45, 2815-2827.	1.6	24
321	The immuno-oncological challenge of COVID-19. Nature Cancer, 2020, 1, 946-964.	5.7	96
322	A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy. Clinical Cancer Research, 2020, 26, 5198-5207.	3.2	66
323	Trial watch: STING agonists in cancer therapy. OncoImmunology, 2020, 9, 1777624.	2.1	148
324	Polycarbonate-based ultra-pH sensitive nanoparticles improve therapeutic window. Nature Communications, 2020, 11, 5828.	5.8	49
325	Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies. Signal Transduction and Targeted Therapy, 2020, 5, 270.	7.1	18

#	Article	IF	Citations
326	Dynamical Boolean Modeling of Immunogenic Cell Death. Frontiers in Physiology, 2020, 11, 590479.	1.3	13
327	P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers. Frontiers in Oncology, 2020, 10, 576559.	1.3	101
328	The Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer. International Journal of Molecular Sciences, 2020, 21, 8877.	1.8	103
329	Cytokines in oncolytic virotherapy. Cytokine and Growth Factor Reviews, 2020, 56, 4-27.	3.2	33
330	New viral vectors for infectious diseases and cancer. Seminars in Immunology, 2020, 50, 101430.	2.7	55
331	BDCA1⁺ cDC2s, BDCA2⁺ pDCs and BDCA3⁺ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients. Clinical and Translational Immunology, 2020, 9, e1190.	1.7	16
332	Autophagy mediated danger signaling regulates tumor immunosurveillance and may potentiate the effects of anti-cancer immunotherapy through increased adjuvanticity. , 2020, , 119-140.		1
333	A recombinant oncolytic Newcastle virus expressing MIP-3Î± promotes systemic antitumor immunity. , 2020, 8, e000330.		19
334	Fetal HLA-G mediated immune tolerance and interferon response in preeclampsia. EBioMedicine, 2020, 59, 102872.	2.7	25
335	Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer. Oncogene, 2020, 39, 5995-6008.	2.6	12
336	Pseudovirus for immunotherapy. Nature Cancer, 2020, 1, 860-861.	5.7	3
337	Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. OncoImmunology, 2020, 9, 1796002.	2.1	63
338	Self RNA Sensing by RIG-Iâ€“like Receptors in Viral Infection and Sterile Inflammation. Journal of Immunology, 2020, 205, 883-891.	0.4	21
339	DNA methylation repels binding of hypoxia-inducible transcription factors to maintain tumor immunotolerance. Genome Biology, 2020, 21, 182.	3.8	39
340	Molecular characterisation of ILRUN, a novel inhibitor of proinflammatory and antimicrobial cytokines. Heliyon, 2020, 6, e04115.	1.4	15
341	Molecular profiling of immune cell-enriched Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) interacting protein USP13. Life Sciences, 2020, 258, 118170.	2.0	10
342	AIM2 in health and disease: Inflammasome and beyond. Immunological Reviews, 2020, 297, 83-95.	2.8	107
343	Molecular and Structural Basis of DNA Sensors in Antiviral Innate Immunity. Frontiers in Immunology, 2020, 11, 613039.	2.2	54

#	Article	IF	Citations
344	IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives. Vaccines, 2020, 8, 617.	2.1	14
345	Temperature-triggered micellization of interferon alpha-diblock copolypeptide conjugate with enhanced stability and pharmacology. Journal of Controlled Release, 2020, 328, 444-453.	4.8	16
346	Glioma stem-like cells evade interferon suppression through MBD3/NuRD complexâ€“mediated STAT1 downregulation. Journal of Experimental Medicine, 2020, 217, .	4.2	30
347	Pathogen-like Nanoassemblies of Covalently Linked TLR Agonists Enhance CD8 and NK Cell-Mediated Antitumor Immunity. ACS Central Science, 2020, 6, 2071-2078.	5.3	12
348	The transcription factor NFAT5 limits infection-induced type I interferon responses. Journal of Experimental Medicine, 2020, 217, .	4.2	14
349	Hypoxia Induces Transcriptional and Translational Downregulation of the Type I IFN Pathway in Multiple Cancer Cell Types. Cancer Research, 2020, 80, 5245-5256.	0.4	46
350	CBX3 Promotes Gastric Cancer Progression and Affects Factors Related to Immunotherapeutic Responses . Cancer Management and Research, 2020, Volume 12, 10113-10125.	0.9	23
351	The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration. Molecular Therapy - Nucleic Acids, 2020, 22, 373-381.	2.3	33
352	Primary and metastatic breast tumors cross-talk to influence immunotherapy responses. OncoImmunology, 2020, 9, 1802979.	2.1	5
353	Genetic Engineering as a Strategy to Improve the Therapeutic Efficacy of Mesenchymal Stem/Stromal Cells in Regenerative Medicine. Frontiers in Cell and Developmental Biology, 2020, 8, 737.	1.8	52
354	BATF2 expression as a novel marker for invasive phenotype in malignant melanoma. Journal of Dermatology, 2020, 47, e372-e373.	0.6	2
355	Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity. Science Advances, 2020, 6, eabc3646.	4.7	92
356	Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. Molecular Cancer, 2020, 19, 141.	7.9	141
357	Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment. Biomacromolecules, 2020, 21, 3704-3712.	2.6	44
358	Single-cell RNA sequencing of immune cells in gastric cancer patients. Aging, 2020, 12, 2747-2763.	1.4	36
359	Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Research, 2020, 30, 966-979.	5.7	349
360	Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. Npj Precision Oncology, 2020, 4, 29.	2.3	11
361	Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer. Cancers, 2020, 12, 3197.	1.7	16

#	Article	IF	Citations
362	Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. Breast Cancer Research and Treatment, 2020, 181, 541-551.	1.1	22
363	Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity. Seminars in Radiation Oncology, 2020, 30, 129-138.	1.0	27
364	Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers. Cancer Biology and Therapy, 2020, 21, 629-636.	1.5	7
365	ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 11471-11482.	3.3	39
366	Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment. Cell Death and Disease, 2020, 11, 361.	2.7	30
367	Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer. Nano Letters, 2020, 20, 4393-4402.	4.5	93
368	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. Cancers, 2020, 12, 1502.	1.7	145
369	Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion. Cells, 2020, 9, 1405.	1.8	20
370	MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. Nature Communications, 2020, 11, 2860.	5.8	45
371	Pediatric cancer research: Surviving COVIDâ€19. Pediatric Blood and Cancer, 2020, 67, e28435.	0.8	28
372	Tâ€cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. Clinical and Translational Medicine, 2020, 10, e39.	1.7	46
373	pHâ€Responsive STINGâ€Activating DNA Nanovaccines for Cancer Immunotherapy. Advanced Therapeutics, 2020, 3, 2000083.	1.6	22
374	Trial watch: TLR3 agonists in cancer therapy. OncoImmunology, 2020, 9, 1771143.	2.1	116
375	Regulation of Cancer Immune Checkpoints. Advances in Experimental Medicine and Biology, 2020, , .	0.8	7
376	Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. Cancer Cell, 2020, 37, 354-370.e7.	7.7	34
377	Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-Î±-induced apoptosis in tumor-repopulating cells of melanoma. , 2020, 8, e000111.		22
378	A Dual Role of Type I Interferons in Antitumor Immunity. Advanced Biology, 2020, 4, e1900237.	3.0	23
379	RIG-I-like receptors: their regulation and roles in RNA sensing. Nature Reviews Immunology, 2020, 20, 537-551.	10.6	838

#	Article	IF	Citations
380	NK cells mediate clearance of CD8 ⁺ T cellâ€“resistant tumors in response to STING agonists. Science Immunology, 2020, 5, .	5.6	128
381	Tumor Microenvironment. Cancer Treatment and Research, 2020, , .	0.2	12
382	Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response . International Journal of Nanomedicine, 2020, Volume 15, 1499-1515.	3.3	16
383	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular and Molecular Immunology, 2020, 17, 807-821.	4.8	1,136
384	Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. Cancers, 2020, 12, 1763.	1.7	17
385	Nucleic Acid Sensors as Therapeutic Targets for Human Disease. Immunity, 2020, 53, 78-97.	6.6	44
386	Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. OncoImmunology, 2020, 9, 1789284.	2.1	4
387	Interferon-Î² exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity. Neuro-Oncology Advances, 2020, 2, vdaa043.	0.4	3
388	Melanoma suppression by quercein is correlated with RIG-I and type I interferon signaling. Biomedicine and Pharmacotherapy, 2020, 125, 109984.	2.5	20
389	The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment. Journal of Clinical Medicine, 2020, 9, 519.	1.0	26
390	Measles Vaccines Designed for Enhanced CD8+ T Cell Activation. Viruses, 2020, 12, 242.	1.5	15
391	Endogenous Retrovirus Activation as a Key Mechanism of Anti-Tumor Immune Response in Radiotherapy. Radiation Research, 2020, 193, 305.	0.7	33
392	Regulation of cancerâ€immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1612.	3.3	33
393	Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP. Immunity, 2020, 52, 357-373.e9.	6.6	235
394	oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity. Molecular Therapy - Oncolytics, 2020, 16, 158-171.	2.0	17
395	Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma. Cells, 2020, 9, 417.	1.8	32
396	COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death. Cancer Letters, 2020, 476, 106-119.	3.2	7
397	Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy. Cell Communication and Signaling, 2020, 18, 8.	2.7	16

#	Article	IF	Citations
398	Type I Interferon Regulates a Coordinated Gene Network to Enhance Cytotoxic T Cellâ€“Mediated Tumor Killing. Cancer Discovery, 2020, 10, 382-393.	7.7	31
399	Cytokines as potential combination agents with PDâ€1/PDâ€L1 blockade for cancer treatment. Journal of Cellular Physiology, 2020, 235, 5449-5460.	2.0	42
400	Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nature Communications, 2020, 11, 524.	5.8	29
401	Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment?. Journal of Translational Medicine, 2020, 18, 45.	1.8	44
402	Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. Immunity, 2020, 52, 36-54.	6.6	127
403	Immunomodulation by anticancer cell cycle inhibitors. Nature Reviews Immunology, 2020, 20, 669-679.	10.6	86
404	Tumor Milieu Controlled by RB Tumor Suppressor. International Journal of Molecular Sciences, 2020, 21, 2450.	1.8	17
405	The Interactions Between Cancer Stem Cells and the Innate Interferon Signaling Pathway. Frontiers in Immunology, 2020, 11, 526.	2.2	30
406	TBK1 and IKKÎµ Act Redundantly to Mediate STING-Induced NF-ÎºB Responses in Myeloid Cells. Cell Reports, 2020, 31, 107492.	2.9	223
407	MicroRNA binding site polymorphism in inflammatory genes associated with colorectal cancer: literature review and bioinformatics analysis. Cancer Gene Therapy, 2020, 27, 739-753.	2.2	23
408	EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. Nature Cancer, 2020, 1, 394-409.	5.7	51
409	A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Science Advances, 2020, 6, eaaw6071.	4.7	152
410	Peritumoral administration of IFNÎ² upregulated mesenchymal stem cells inhibits tumor growth in an orthotopic, immunocompetent rat glioma model. , 2020, 8, e000164.		12
411	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
412	Calreticulin and cancer. Cell Research, 2021, 31, 5-16.	5.7	174
413	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood, 2021, 137, 216-231.	0.6	40
414	Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy. Biomaterials, 2021, 264, 120447.	5.7	19
415	Suppression of CCDC6 sensitizes tumor to oncolytic virus M1. Neoplasia, 2021, 23, 158-168.	2.3	8

#	Article	IF	Citations
416	Double-edged effects of interferons on the regulation of cancer-immunity cycle. OncoImmunology, 2021, 10, 1929005.	2.1	18
417	Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. Journal of Clinical Investigation, 2021, 131, .	3.9	48
418	Cytosolic sensor STING in mucosal immunity: a master regulator of gut inflammation and carcinogenesis. Journal of Experimental and Clinical Cancer Research, 2021, 40, 39.	3.5	10
419	Tumor-suppressor function of Beclin 1 in breast cancer cells requires E-cadherin. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	50
420	Calreticulin Exposure in Mitotic Catastrophe. Methods in Molecular Biology, 2021, 2267, 207-215.	0.4	1
421	Dormant Tumor Cell Vaccination: A Mathematical Model of Immunological Dormancy in Triple-Negative Breast Cancer. Cancers, 2021, 13, 245.	1.7	11
422	Emerging roles of DYRK2 in cancer. Journal of Biological Chemistry, 2021, 296, 100233.	1.6	34
423	Role of Infections and Tissue Inflammation in the Pathology of the Fallopian Tube and High-Grade Serous Ovarian Cancer. Physiology in Health and Disease, 2021, , 271-312.	0.2	0
424	The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets. BMB Reports, 2021, 54, 31-43.	1.1	33
425	Association between Inflammation and Function of Cell Adhesion Molecules Influence on Gastrointestinal Cancer Development. Cells, 2021, 10, 67.	1.8	18
426	Type I Interferons as Joint Regulators of Tumor Growth and Obesity. Cancers, 2021, 13, 196.	1.7	9
427	Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nature Communications, 2021, 12, 832.	5.8	248
428	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Seminars in Cancer Biology, 2022, 84, 89-102.	4.3	21
429	Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	38
430	TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense. Viruses, 2021, 13, 279.	1.5	18
431	SILAC-Based Quantitative Proteomic Analysis of Oxaliplatin-Resistant Pancreatic Cancer Cells. Cancers, 2021, 13, 724.	1.7	11
432	Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation. Cancer Research, 2021, 81, 2171-2183.	0.4	14
433	Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nature Biomedical Engineering, 2021, 5, 455-466.	11.6	157

#	Article	IF	Citations
434	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduction and Targeted Therapy, 2021, 6, 72.	7.1	191
435	Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. Kaohsiung Journal of Medical Sciences, 2021, 37, 448-458.	0.8	15
436	Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Science Translational Medicine, 2021, 13, .	5.8	35
437	Glyco-Nanoadjuvants: Sugar Structures on Carriers of a Small Molecule TLR7 Ligand Affect Their Immunostimulatory Activities. ACS Applied Bio Materials, 2021, 4, 2732-2741.	2.3	5
438	Novel therapeutic targets for chronic myelomonocytic leukemia. Best Practice and Research in Clinical Haematology, 2021, 34, 101244.	0.7	2
439	Type I and II Interferons in the Anti-Tumor Immune Response. Cancers, 2021, 13, 1037.	1.7	47
440	Role of Periostin Expression in Canine Osteosarcoma Biology and Clinical Outcome. Veterinary Pathology, 2021, 58, 981-993.	0.8	2
441	Autophagy in inflammation, infection, and immunometabolism. Immunity, 2021, 54, 437-453.	6.6	333
442	Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. Frontiers in Oncology, 2021, 11, 626818.	1.3	13
443	Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. Nature Communications, 2021, 12, 1858.	5.8	47
444	Manganese salts function as potent adjuvants. Cellular and Molecular Immunology, 2021, 18, 1222-1234.	4.8	106
445	The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STINGâ€“IFN-Î² pathway. Nature Immunology, 2021, 22, 485-496.	7.0	45
446	Neoadjuvant Pembrolizumab and High-Dose IFNÎ±-2b in Resectable Regionally Advanced Melanoma. Clinical Cancer Research, 2021, 27, 4195-4204.	3.2	18
447	Maintaining manganese in tumor to activate cGAS-STING pathway evokes a robust abscopal anti-tumor effect. Journal of Controlled Release, 2021, 331, 480-490.	4.8	66
448	Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. Nature Communications, 2021, 12, 1717.	5.8	53
449	cGASâ€“STING cytosolic DNA sensing pathway is suppressed by JAK2-STAT3 in tumor cells. Scientific Reports, 2021, 11, 7243.	1.6	36
450	Comprehensive description of the current breast cancer microenvironment advancements via single-cell analysis. Journal of Experimental and Clinical Cancer Research, 2021, 40, 142.	3.5	20
451	Bortezomib Induces Antiâ€“Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. Blood Cancer Discovery, 2021, 2, 468-483.	2.6	64

#	Article	IF	Citations
452	Epigenetic reprogramming of tumor cellâ€“intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	78
453	The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Molecular Cancer, 2021, 20, 76.	7.9	42
454	Degradation Products of Complex Arabinoxylans by Bacteroides intestinalis Enhance the Host Immune Response. Microorganisms, 2021, 9, 1126.	1.6	16
455	Induced pluripotent stem cell-derived, genetically engineered myeloid cells as unlimited cell source for dendritic cell-related cancer immunotherapy. Journal of Immunology and Regenerative Medicine, 2021, 12, 100042.	0.2	0
456	Tumor Immunity and Immunotherapy for HPV-Related Cancers. Cancer Discovery, 2021, 11, 1896-1912.	7.7	71
457	Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity. Cancers, 2021, 13, 2249.	1.7	28
458	STING Agonists as Cancer Therapeutics. Cancers, 2021, 13, 2695.	1.7	181
459	Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treatment Reviews, 2021, 101, 102227.	3.4	42
460	Signalâ€transducing innate receptors in tumor immunity. Cancer Science, 2021, 112, 2578-2591.	1.7	8
461	Critical role of interferons in gastrointestinal injury repair. Nature Communications, 2021, 12, 2624.	5.8	42
462	Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer. Viruses, 2021, 13, 1019.	1.5	2
463	Harnessing Genomic Stress for Antitumor Immunity. Antioxidants and Redox Signaling, 2021, 34, 1128-1150.	2.5	5
464	A Monocyte-Orchestrated IFN-Iâ€“toâ€“IL-4 Cytokine Axis Instigates Protumoral Macrophages and Thwarts Poly(I:C) Therapy. Journal of Immunology, 2021, 207, 408-420.	0.4	3
465	Oncolytic virotherapy: Potentially a game-changing tumor treatment. Cancer Cell, 2021, 39, 753-755.	7.7	9
466	Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma. Frontiers in Oncology, 2021, 11, 675873.	1.3	7
467	Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma. Frontiers in Oncology, 2021, 11, 684025.	1.3	6
468	Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy. Frontiers in Oncology, 2021, 11, 695770.	1.3	9
469	Depletion of DNA Polymerase Theta Inhibits Tumor Growth and Promotes Genome Instability through the cGAS-STING-ISG Pathway in Esophageal Squamous Cell Carcinoma. Cancers, 2021, 13, 3204.	1.7	9

#	Article	IF	Citations
470	Type I Interferon Signaling Accelerates Liver Regeneration by Metabolic Modulation in Noninfectious Conditions. American Journal of Pathology, 2021, 191, 1036-1048.	1.9	4
471	Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy. AAPS Journal, 2021, 23, 90.	2.2	19
472	Transcriptome and genome evolution during HER2-amplified breast neoplasia. Breast Cancer Research, 2021, 23, 73.	2.2	2
473	Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor ResponsesIn Vivo. Molecular Cancer Therapeutics, 2021, 20, 1941-1955.	1.9	41
474	Immunology and Immune Checkpoint Inhibition in Ovarian Cancer â€“ Current Aspects. Geburtshilfe Und Frauenheilkunde, 2021, 81, 1128-1144.	0.8	10
475	Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduction and Targeted Therapy, 2021, 6, 263.	7.1	739
476	Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis. Frontiers in Molecular Neuroscience, 2021, 14, 710171.	1.4	6
477	Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy. Acta Biomaterialia, 2021, 134, 702-715.	4.1	28
478	Photothermal Therapy Combined with Neoantigen Cancer Vaccination for Effective Immunotherapy against Large Established Tumors and Distant Metastasis. Advanced Therapeutics, 2021, 4, 2100093.	1.6	20
479	Chitosan-Poly(Acrylic Acid) Nanoparticles Loaded with R848 and MnCl2 Inhibit Melanoma via Regulating Macrophage Polarization and Dendritic Cell Maturation. International Journal of Nanomedicine, 2021, Volume 16, 5675-5692.	3.3	10
480	From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment. Frontiers in Oncology, 2021, 11, 728018.	1.3	63
481	Autophagy in major human diseases. EMBO Journal, 2021, 40, e108863.	3.5	615
482	Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol. Cancers, 2021, 13, 3902.	1.7	18
483	Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic. International Journal of Radiation Oncology Biology Physics, 2021, 111, e38-e53.	0.4	2
484	Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?. Cancer Discovery, 2021, 11, 2396-2412.	7.7	81
485	Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors. Biomaterials, 2021, 275, 120914.	5.7	40
486	IFNÎ² Is a Potent Adjuvant for Cancer Vaccination Strategies. Frontiers in Immunology, 2021, 12, 735133.	2.2	11
487	Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?. Biology, 2021, 10, 913.	1.3	2

#	Article	IF	Citations
488	The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation. Biology, 2021, 10, 856.	1.3	21
489	Inflammation-Immunity-Nutrition Score: A Novel Prognostic Score for Patients with Resectable Colorectal Cancer. Journal of Inflammation Research, 2021, Volume 14, 4577-4588.	1.6	7
490	Type I Interferon Induction and Exhaustion during Viral Infection: Plasmacytoid Dendritic Cells and Emerging COVID-19 Findings. Viruses, 2021, 13, 1839.	1.5	21
491	Beyond the Double-Strand Breaks: The Role of DNA Repair Proteins in Cancer Stem-Cell Regulation. Cancers, 2021, 13, 4818.	1.7	20
492	The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications. British Journal of Dermatology, 2021, , .	1.4	9
493	Overview of vaccine adjuvants. Medicine in Drug Discovery, 2021, 11, 100103.	2.3	18
494	Activating a collaborative innate-adaptive immune response to control metastasis. Cancer Cell, 2021, 39, 1361-1374.e9.	7.7	122
495	T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy. Nature Nanotechnology, 2021, 16, 1271-1280.	15.6	75
496	Targeting cytokinesis bridge proteins to kill high-CIN type tumors. Fundamental Research, 2021, 1, 752-766.	1.6	5
497	(S)-(-)-N-[2-(3-Hydroxy-2-oxo-2,3-dihydro-1H-indol-3-yl)-ethyl]-acetamide inhibits colon cancer growth via the STAT1 pathway. Food Science and Technology, 0, , .	0.8	0
498	Effects of lactate in immunosuppression and inflammation: Progress and prospects. International Reviews of Immunology, 2022, 41, 19-29.	1.5	25
499	PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Cancer Cell, 2021, 39, 1214-1226.e10.	7.7	72
500	Impact of Type I Interferons on Susceptibility to Bacterial Pathogens. Trends in Microbiology, 2021, 29, 823-835.	3.5	25
501	Design, synthesis, molecular docking and DFT computational insight on the structure of Piperazine sulfynol derivatives as a new antibacterial contender against superbugs MRSA. Journal of Molecular Structure, 2022, 1247, 131333.	1.8	19
502	Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment. Cancers, 2021, 13, 433.	1.7	22
503	Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. Cancers, 2021, 13, 373.	1.7	18
504	Immunogenic Cell Death Driven by Radiationâ€"Impact on the Tumor Microenvironment. Cancer Treatment and Research, 2020, 180, 281-296.	0.2	10
505	The Cross-Regulation Between Autophagy and Type I Interferon Signaling in Host Defense. Advances in Experimental Medicine and Biology, 2019, 1209, 125-144.	0.8	5

#	Article	IF	Citations
506	Exosome and Secretion: Action On?. Advances in Experimental Medicine and Biology, 2020, 1248, 455-483.	0.8	13
507	Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors. Cancer Immunology, Immunotherapy, 2018, 67, 445-457.	2.0	19
508	Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics. Acta Pharmacologica Sinica, 2020, 41, 881-894.	2.8	19
509	Cancer immune resistance: can theories converge?. Emerging Topics in Life Sciences, 2017, 1, 411-419.	1.1	13
510	JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML. Journal of Experimental Medicine, 2021, 218, .	4.2	22
520	cGAS/STING axis mediates a topoisomerase II inhibitorâ€“induced tumor immunogenicity. Journal of Clinical Investigation, 2019, 129, 4850-4862.	3.9	136
521	p53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus. Journal of Clinical Investigation, 2019, 129, 4875-4884.	3.9	24
522	HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. Journal of Clinical Investigation, 2020, 130, 1635-1652.	3.9	104
523	Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. Journal of Clinical Investigation, 2020, 130, 5951-5966.	3.9	72
524	Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. Journal of Clinical Investigation, 2020, 130, 1912-1930.	3.9	268
525	The host STING pathway at the interface of cancer and immunity. Journal of Clinical Investigation, 2016, 126, 2404-2411.	3.9	327
526	Dinaciclib induces immunogenic cell death and enhances anti-PD1â€“mediated tumor suppression. Journal of Clinical Investigation, 2018, 128, 644-654.	3.9	144
527	PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. Journal of Clinical Investigation, 2018, 128, 1413-1428.	3.9	111
528	Impact of Interferon-alpha1b (IFN-Î±1b) on Antitumor Immune Response: An Interpretation of the Promising Therapeutic Effect of IFN-alpha1b on Melanoma. Medical Science Monitor, 2020, 26, e922790.	0.5	5
529	ACTION INTERFERONS AND IFN-INDUCTORS ON TLR/RLRS GENES EXPRESSION AND DIFFERENTIATION OF TUMOR CELL LINES THP-1 AND HCT-116. , 2016, 15, 28-33.	0.3	4
530	Development of Higher Molecular Weight of Recombinant Human Interferon Alpha-2a by Albumin Fusion Technology in Methilotropic Yeast Pichia Pastoris. International Journal on Advanced Science, Engineering and Information Technology, 2017, 7, 8.	0.2	2
531	Concerted action of IFN-Î± and IFN-Î» induces local NK cell immunity and halts cancer growth. Oncotarget, 2016, 7, 49259-49267.	0.8	23
532	Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Oncotarget, 2016, 7, 79828-79841.	0.8	53

#	Article	IF	Citations
533	Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model. Oncotarget, 2017, 8, 5247-5255.	0.8	10
534	Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells. Oncotarget, 2018, 9, 1785-1802.	0.8	12
535	Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget, 2018, 9, 28702-28716.	0.8	27
536	ST2/IL-33 signaling promotes malignant development of experimental squamous cell carcinoma by decreasing NK cells cytotoxicity and modulating the intratumoral cell infiltrate. Oncotarget, 2018, 9, 30894-30904.	0.8	16
537	Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses. Oncotarget, 2019, 10, 7220-7237.	0.8	11
538	Recombinant poliovirus for cancer immunotherapy. Annals of Translational Medicine, 2018, 6, 368-368.	0.7	4
539	Harnessing Tumor Immune Ecosystem Dynamics to Personalize Radiation Therapy. SSRN Electronic Journal, 0, , .	0.4	2
540	Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials. Radiology and Oncology, 2020, 54, 377-393.	0.6	16
541	â€œToll-freeâ€•pathways for production of type I interferons. AIMS Allergy and Immunology, 2017, 1, 143-163.	0.3	9
542	CD1a+ and CD207+ cells are reduced in oral submucous fibrosis and oral squamous cell carcinoma. Medicina Oral, Patologia Oral Y Cirugia Bucal, 2020, 25, e49-e55.	0.7	23
543	Identification of a risk prediction model for clinical prognosis in HER2 positive breast cancer patients. Genomics, 2021, 113, 4088-4097.	1.3	8
544	Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell, 2021, 184, 5338-5356.e21.	13.5	229
545	Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts. Oncogene, 2022, 41, 112-124.	2.6	6
546	Microbiomics in Collusion with the Nervous System in Carcinogenesis: Diagnosis, Pathogenesis and Treatment. Microorganisms, 2021, 9, 2129.	1.6	3
547	Comprehensive Analysis to Identify the Epithelialâ€“Mesenchymal Transition-Related Immune Signatures as a Prognostic and Therapeutic Biomarkers in Hepatocellular Carcinoma. Frontiers in Surgery, 2021, 8, 742443.	0.6	5
548	Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. Frontiers in Immunology, 2021, 12, 721830.	2.2	50
549	Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions. Nature Communications, 2021, 12, 6012.	5.8	140
550	Interferon alpha induces the apoptosis of cervical cancer HeLa cells by activating both the Intrinsic Mitochondrial pathway and ER Stress-induced pathway. , 0, , .		0

#	Article	IF	Citations
551	Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkinâ€™s Lymphoma. International Journal of Biomedicine, 2015, 5, 214-218.	0.1	0
552	TLR3 Is a Death Receptor Target in Cancer Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 159-185.	0.1	0
554	Endogenous DAMPs, Category III: Inducible DAMPs (Cat. III DAMPs). , 2018, , 307-351.		1
555	Future prospects for breast cancer immunotherapy. Meditsinskiy Sovet, 2018, , 12-16.	0.1	0
557	Effect of Interferon Î±-2b on Multicellular Tumor Spheroids of MCF-7 Cell Line Enriched with Cancer Stem Cells. Innovative Biosystems and Bioengineering, 2019, 3, 34-44.	0.2	2
560	Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. , 2021, 9, e002917.		27
561	Targeted Stat2 deletion in conventional dendritic cells impairs CTL responses but does not affect antibody production. OncoImmunology, 2021, 10, 1860477.	2.1	5
562	Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy. Cancers, 2021, 13, 49.	1.7	7
563	Pegylation and Cell Based Bioassay of Human Interferon-Î±2b Along its Docking Studies and Effect on Plasma Half-Life. Protein and Peptide Letters, 2020, 27, 219-224.	0.4	2
564	The Role of Plasmacytoid Dendritic Cells in Cancers. Frontiers in Immunology, 2021, 12, 749190.	2.2	33
565	Type I Interferon Promotes Antitumor T Cell Response in CRPC by Regulating MDSC. Cancers, 2021, 13, 5574.	1.7	4
569	Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies. Oncology, 2016, 30, 59-66, 69.	0.4	14
570	Revisiting Lung Cancer Metastasis: Insight From the Functions of Long Non-coding RNAs. Technology in Cancer Research and Treatment, 2021, 20, 15330338211038488.	0.8	0
571	Spatial transcriptomics reveals gene expression characteristics in invasive micropapillary carcinoma of the breast. Cell Death and Disease, 2021, 12, 1095.	2.7	21
572	Bridging Radiotherapy to Immunotherapy: The IFNâ€“JAKâ€“STAT Axis. International Journal of Molecular Sciences, 2021, 22, 12295.	1.8	13
573	Tumor-derived extracellular vesicles regulate tumor-infiltrating regulatory T cells via the inhibitory immunoreceptor CD300a. ELife, 2021, 10, .	2.8	14
574	Hypoxia Regulates Endogenous Double-Stranded RNA Production via Reduced Mitochondrial DNA Transcription. Frontiers in Oncology, 2021, 11, 779739.	1.3	13
575	Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer. Frontiers in Oncology, 2021, 11, 734853.	1.3	14

#	Article	IF	Citations
576	Structure and expression identification of Cherry Valley duck IRF8. Poultry Science, 2022, 101, 101598.	1.5	1
577	Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer. Frontiers in Oncology, 2021, 11, 747012.	1.3	3
578	The Leptin Axis and Its Association With the Adaptive Immune System in Breast Cancer. Frontiers in Immunology, 2021, 12, 784823.	2.2	10
579	WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. Journal of Experimental Medicine, 2022, 219, .	4.2	22
580	Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ TÂcell immunity. Immunity, 2022, 55, 308-323.e9.	6.6	126
581	Interferon Signaling in Estrogen Receptorâ€“positive Breast Cancer: A Revitalized Topic. Endocrinology, 2022, 163, .	1.4	16
582	Oncolytic Activity of Wild-type Newcastle Disease Virus HK84 Against Hepatocellular Carcinoma Associated with Activation of Type I Interferon Signaling. Journal of Clinical and Translational Hepatology, 2022, 10, 284-296.	0.7	10
583	Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers. PLoS ONE, 2021, 16, e0260500.	1.1	2
584	Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. Molecular Therapy - Oncolytics, 2022, 24, 59-76.	2.0	8
585	Type I interferons: One stone to concurrently kill two birds, viral infections and cancers. Current Research in Virological Science, 2021, 2, 100014.	1.8	5
586	Interval breast cancer is associated with interferon immune response. European Journal of Cancer, 2022, 162, 194-205.	1.3	3
587	Revisiting Lung Cancer Metastasis: Insight From the Functions of Long Non-coding RNAs. Technology in Cancer Research and Treatment, 2021, 20, 153303382110384.	0.8	2
588	NLRP4 negatively regulates type I interferon response and influences the outcome in antiâ€programmed cell death protein (PD)â€1/PDâ€ligand 1 therapy. Cancer Science, 2021, , .	1.7	7
589	Gospel of malignant Glioma: Oncolytic virus therapy. Gene, 2022, 818, 146217.	1.0	17
590	Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy. Japanese Journal of Radiology, 2022, 40, 458-465.	1.0	2
591	Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy. Acta Biomaterialia, 2022, 141, 398-407.	4.1	21
592	Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers. Nanoscale, 2022, 14, 1144-1159.	2.8	11
593	DNA Damage Repair in Brain Tumor Immunotherapy. Frontiers in Immunology, 2021, 12, 829268.	2.2	3

#	Article	IF	Citations
594	Functions and roles of IFIX, a member of the human HIN-200 family, in human diseases. Molecular and Cellular Biochemistry, 2022, 477, 771-780.	1.4	1
596	High Expression of Interferon Pathway Genes CXCL10 and STAT2 Is Associated with Activated T-Cell Signature and Better Outcome of Oral Cancer Patients. Journal of Personalized Medicine, 2022, 12, 140.	1.1	7
597	Assessment of type I interferon responses as a feature of immunogenic cell death. Methods in Cell Biology, 2022, , 135-143.	0.5	4
598	Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma. Molecular Therapy - Oncolytics, 2022, 24, 522-534.	2.0	17
599	A Variety of Nucleic Acid Species Are Sensed by cGAS, Implications for Its Diverse Functions. Frontiers in Immunology, 2022, 13, 826880.	2.2	10
600	Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors. ACS Nano, 2022, 16, 4426-4443.	7.3	33
601	Targeting transgenic proteins to alpha granules for platelet-directed gene therapy. Molecular Therapy - Nucleic Acids, 2022, 27, 774-786.	2.3	3
602	Immunogenic cell stress and death. Nature Immunology, 2022, 23, 487-500.	7.0	434
603	Mesenchymal stromal cells equipped by IFNÎ± empower T cells with potent anti-tumor immunity. Oncogene, 2022, 41, 1866-1881.	2.6	9
605	MnO₂nanoparticles as a minimalist multimode vaccine adjuvant/delivery system to regulate antigen presenting cells for tumor immunotherapy. Journal of Materials Chemistry B, 2022, 10, 3474-3490.	2.9	8
606	Intravenous Vaccination Induces CD8 ⁺ T Cells and Type I IFN-Dependent Remodeling of the Tumor Microenvironment. SSRN Electronic Journal, 0, , .	0.4	0
607	The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation. Blood, 2022, 139, 2770-2781.	0.6	22
608	Ghost mitochondria drive metastasis through adaptive GCN2/Akt therapeutic vulnerability. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	12
609	Bystander T cells in cancer immunology and therapy. Nature Cancer, 2022, 3, 143-155.	5.7	47
610	Cell membrane coated-nanoparticles for cancer immunotherapy. Acta Pharmaceutica Sinica B, 2022, 12, 3233-3254.	5.7	61
611	Role of Hypoxia in the Interferon Response. Frontiers in Immunology, 2022, 13, 821816.	2.2	5
612	Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities. Current Cancer Drug Targets, 2022, 22, 437-453.	0.8	2
613	Advance of SOX Transcription Factors in Hepatocellular Carcinoma: From Role, Tumor Immune Relevance to Targeted Therapy. Cancers, 2022, 14, 1165.	1.7	6

#	Article	IF	Citations
614	The Transcription Factor IRF9 Promotes Colorectal Cancer via Modulating the IL-6/STAT3 Signaling Axis. Cancers, 2022, 14, 919.	1.7	6
615	Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC. Frontiers in Cell and Developmental Biology, 2022, 10, 816517.	1.8	4
616	Predictive and Prognostic Role of Peripheral Blood T-Cell Subsets in Triple-Negative Breast Cancer. Frontiers in Oncology, 2022, 12, 842705.	1.3	9
617	Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer. Acta Pharmaceutica Sinica B, 2022, 12, 3726-3738.	5.7	15
618	Type I interferon-mediated tumor immunity and its role in immunotherapy. Cellular and Molecular Life Sciences, 2022, 79, 191.	2.4	86
619	Tumor-Associated Macrophages in Gliomasâ€"Basic Insights and Treatment Opportunities. Cancers, 2022, 14, 1319.	1.7	40
620	Glyco-Nanoadjuvants: Impact of Linker Length for Conjugating a Synthetic Small-Molecule TLR7 Ligand to Glyco-Nanoparticles on Immunostimulatory Effects. ACS Chemical Biology, 2022, , .	1.6	5
621	Apoptotic Body-Mediated Intracellular Delivery Strategy for Enhanced STING Activation and Improved Tumor Immunogenicity. Nano Letters, 2022, 22, 2217-2227.	4.5	18
622	Molecular Mechanisms of Tumor Immunomodulation in the Microenvironment of Colorectal Cancer. International Journal of Molecular Sciences, 2022, 23, 2782.	1.8	11
623	The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy. International Journal of Molecular Sciences, 2022, 23, 3871.	1.8	14
624	The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 635-647.	0.4	11
626	TGFÎ² receptor inhibition unleashes interferon-Î² production by tumor-associated macrophages and enhances radiotherapy efficacy. , 2022, 10, e003519.		13
627	The pleiotropic roles of cGASâ€"STING signaling in the tumor microenvironment. Journal of Molecular Cell Biology, 2022, 14, .	1.5	7
628	circREEP3 Drives Colorectal Cancer Progression via Activation of FKBP10 Transcription and Restriction of Antitumor Immunity. Advanced Science, 2022, 9, e2105160.	5.6	16
629	Loss of IRF7 accelerates acute myeloid leukemia progression and induces VCAM1-VLA-4 mediated intracerebral invasion. Oncogene, 2022, 41, 2303-2314.	2.6	11
630	Coâ€occurrence of CDKN2A/B and IFNâ€ homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma. Molecular Oncology, 2022, 16, 1746-1760.	2.1	6
631	Cowpea Mosaic Virus Outperforms Other Members of the Secoviridae as In Situ Vaccine for Cancer Immunotherapy. Molecular Pharmaceutics, 2022, 19, 1573-1585.	2.3	13
632	Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer. Cancer Research Communications, 2022, 2, 246-257.	0.7	4

#	Article	IF	Citations
633	E3 Ubiquitin Ligase Riplet Is Expressed in T Cells and Suppresses T Cellâ€“Mediated Antitumor Immune Responses. Journal of Immunology, 2022, 208, 2067-2076.	0.4	4
634	The spectrum of sex differences in cancer. Trends in Cancer, 2022, 8, 303-315.	3.8	38
635	The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKÎµ/TBK1/IRF3 pathway in head and neck squamous cell carcinoma. Molecular Cancer, 2022, 21, 97.	7.9	42
636	<scp>Homologous recombination deficiency</scp> is inversely correlated with <scp>microsatellite instability</scp> and identifies immunologically cold tumors in most cancer types. Journal of Pathology: Clinical Research, 2022, 8, 371-382.	1.3	10
637	Targeting Cancer Stem Cells through Epigenetic Modulation of Interferon Response. Journal of Personalized Medicine, 2022, 12, 556.	1.1	4
638	A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA. Journal of Controlled Release, 2022, 345, 354-370.	4.8	14
639	Identification of Candidate Target Genes and Immune Cells in Oral Squamous Cell Carcinoma. Computational and Mathematical Methods in Medicine, 2021, 2021, 1-14.	0.7	2
640	IFI16 inhibits DNA repair that potentiates type-I interferon-induced antitumor effects in triple negative breast cancer. Cell Reports, 2021, 37, 110138.	2.9	24
643	Emerging role of RNA sensors in tumor microenvironment and immunotherapy. Journal of Hematology and Oncology, 2022, 15, 43.	6.9	11
644	Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy. Frontiers in Immunology, 2022, 13, 865964.	2.2	9
645	Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs. Food and Chemical Toxicology, 2022, 164, 113008.	1.8	70
662	Albumin and interferon-Î² fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity. , 2022, 10, e004342.		8
663	Diversification of circulating and tumorâ€infiltrating plasmacytoid DCs towards the P3 (CD80⁺ PDL1^{â^'})â€pDC subset negatively correlated with clinical outcomes in melanoma patients. Clinical and Translational Immunology, 2022, 11, e1382.	1.7	6
664	Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination. Clinical and Translational Immunology, 2022, 11, e1392.	1.7	0
665	Manipulation of the tumor immuno-microenvironment via TAM-targeted expression of transcription factors. Immunologic Research, 2022, 70, 432-440.	1.3	5
666	Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications. Frontiers in Immunology, 2022, 13, 816642.	2.2	18
667	Quality by Design for enabling RNA platform production processes. Trends in Biotechnology, 2022, 40, 1213-1228.	4.9	36
668	Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysis. Therapie, 2022, 77, 649-656.	0.6	6

#	Article	IF	Citations
669	The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis. Molecular Cancer, 2022, 21, 110.	7.9	41
670	Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer. Cancer Discovery, 2022, 12, 1904-1921.	7.7	25
671	Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy. Advanced Drug Delivery Reviews, 2022, 185, 114308.	6.6	23
672	Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens. Frontiers in Immunology, 2022, 13, .	2.2	3
673	Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies. Cancer Immunology, Immunotherapy, 2022, 71, 2985-2998.	2.0	5
674	Interferonâ€Î± and its effects on cancer cell apoptosis (Review). Oncology Letters, 2022, 24, .	0.8	9
675	Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors. OncoImmunology, 2022, 11, .	2.1	30
676	Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity. Nature Cancer, 2022, 3, 734-752.	5.7	12
677	Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. Nature Cancer, 2022, 3, 808-820.	5.7	21
678	Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors. Frontiers in Cellular and Infection Microbiology, 2022, 12, .	1.8	8
679	PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors. OncoImmunology, 2022, 11, .	2.1	19
680	Red Light Phototherapy Using Light-Emitting Diodes Inhibits Melanoma Proliferation and Alters Tumor Microenvironments. Frontiers in Oncology, 0, 12, .	1.3	8
681	Mechanisms regulating transitory suppressive activity of neutrophils in newborns: PMNsâ€MDSCs in newborns. Journal of Leukocyte Biology, 0, , .	1.5	1
682	Estrogen Receptor Signaling in the Immune System. Endocrine Reviews, 2023, 44, 117-141.	8.9	38
683	Tumor-Infiltrating Myeloid Cell Subsets Correlate with Overall Survival in Lung Squamous Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
684	RT-PCR-assisted quantification of type I IFN responses in irradiated cancer cells. Methods in Cell Biology, 2022, , .	0.5	0
685	Immunotherapy: an alternative promising therapeutic approach against cancers. Molecular Biology Reports, 2022, 49, 9903-9913.	1.0	17
686	IFNAR1 Deficiency Impairs Immunostimulatory Properties of Neutrophils in Tumor-Draining Lymph Nodes. Frontiers in Immunology, 0, 13, .	2.2	7

#	Article	IF	Citations
687	Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting. Frontiers in Immunology, 0, 13, .	2.2	23
688	Immunomodulatory antitumor effect of interferonâ€'beta combined with gemcitabine in pancreatic cancer. International Journal of Oncology, 2022, 61, .	1.4	2
690	The systemic effect of type 1 interferon responsiveness on tumor immunotherapy. Nature Immunology, 2022, 23, 1141-1143.	7.0	2
691	Different Roles of Dendritic Cells for Chronic Rhinosinusitis Treatment According to Phenotype. International Journal of Molecular Sciences, 2022, 23, 8032.	1.8	1
692	cGAS/cGAMP/STING signal propagation in the tumor microenvironment: Key role for myeloid cells in antitumor immunity. Radiotherapy and Oncology, 2022, 174, 158-167.	0.3	12
693	An integrin axis induces IFN-Î² production in plasmacytoid dendritic cells. Journal of Cell Biology, 2022, 221, .	2.3	1
695	Identification and Validation of an m7G-Related lncRNAs Signature for Prognostic Prediction and Immune Function Analysis in Endometrial Cancer. Genes, 2022, 13, 1301.	1.0	14
696	Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	142
698	Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nature Immunology, 2022, 23, 1379-1392.	7.0	42
699	Hybrid M13 bacteriophage-based vaccine platform for personalized cancer immunotherapy. Biomaterials, 2022, 289, 121763.	5.7	13
700	Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies. Pharmaceutics, 2022, 14, 1762.	2.0	4
701	Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. , 2022, 10, e004006.		14
702	Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma. Cells, 2022, 11, 2519.	1.8	1
703	Identification of a prognostic classifier based on EMT-related lncRNAs and the function of LINC01138 in tumor progression for lung adenocarcinoma. Frontiers in Molecular Biosciences, 0, 9, .	1.6	2
704	Moderate Low <scp>UVB</scp> Irradiation Modulates Tumorâ€associated Macrophages and Dendritic Cells and Promotes Antitumor Immunity in Tumorâ€bearing Mice ¹. Photochemistry and Photobiology, 0, , .	1.3	1
705	Distinctive gene expression patterns in pregnancy-associated breast cancer. Frontiers in Genetics, 0, 13, .	1.1	3
706	Immunogenic Cell Death Augmented by Manganese Zinc Sulfide Nanoparticles for Metastatic Melanoma Immunotherapy. ACS Nano, 2022, 16, 15471-15483.	7.3	71
707	The redox cycling of STAT2 maintains innate immune homeostasis. Cell Reports, 2022, 40, 111215.	2.9	2

#	Article	IF	Citations
708	Identification of Cytosolic DNA Sensor cGAS-STING as Immune-Related Risk Factor in Renal Carcinoma following Pan-Cancer Analysis. Journal of Immunology Research, 2022, 2022, 1-11.	0.9	2
709	Decoding the signaling cascaded in immunotherapy of cancer. , 2022, , 347-377.		0
710	Identification of tumourâ€infiltrating myeloid subsets associated with overall survival in lung squamous cell carcinoma. Journal of Pathology, 0, , .	2.1	1
711	Cellular Target Deconvolution of Small Molecules Using a Selection-Based Genetic Screening Platform. ACS Central Science, 2022, 8, 1424-1434.	5.3	3
713	Impact of Interferon-Free Direct-Acting Antivirals on the Incidence of Extrahepatic Malignancies in Patients with Chronic Hepatitis C. Digestive Diseases and Sciences, 0, , .	1.1	0
714	Mechano-bioconjugation Strategy Empowering Fusion Protein Therapeutics with Aggregation Resistance, Prolonged Circulation, and Enhanced Antitumor Efficacy. Journal of the American Chemical Society, 2022, 144, 18387-18396.	6.6	7
715	Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer. Cells, 2022, 11, 3028.	1.8	7
716	Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy. , 2022, 10, e005068.		6
717	Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246. British Journal of Cancer, 2022, 127, 2060-2071.	2.9	6
718	Magnetic nanoparticles enhance the cellular immune response of <scp>dendritic cell</scp> tumor vaccines by realizing the cytoplasmic delivery of tumor antigens. Bioengineering and Translational Medicine, 2023, 8, .	3.9	6
719	Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation. Frontiers in Oncology, 0, 12, .	1.3	10
720	Anlotinib Benefits the Î±PDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-18.	1.9	3
721	Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies. , 2022, 10, e004561.		9
722	Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19. Biomedicines, 2022, 10, 2628.	1.4	1
725	Tumor-Infiltrating Dendritic Cells: Decisive Roles in Cancer Immunosurveillance, Immunoediting, and Tumor T Cell Tolerance. Cells, 2022, 11, 3183.	1.8	11
726	Systemic vaccination induces CD8+ TÂcells and remodels the tumor microenvironment. Cell, 2022, 185, 4317-4332.e15.	13.5	71
727	Exploring the immunomodulatory role of virtual memory CD8+ T cells: Role of IFN gamma in tumor growth control. Frontiers in Immunology, 0, 13, .	2.2	3
728	Hsp90Î² inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors. Frontiers in Immunology, 0, 13, .	2.2	4

#	Article	IF	Citations
729	Chemopreventive and anti-tumor potential of vitamin E in preclinical breast cancer studies: A systematic review. Clinical Nutrition ESPEN, 2023, 53, 60-73.	0.5	5
731	Targeting STING for cancer immunotherapy: From mechanisms to translation. International Immunopharmacology, 2022, 113, 109304.	1.7	11
732	DNA methyltransferase inhibition promotes recruitment of myeloid-derived suppressor cells to the tumor microenvironment through induction of tumor cell-intrinsic interleukin-1. Cancer Letters, 2023, 552, 215982.	3.2	4
733	Immune cellâ€“camouflaged surface-engineered nanotherapeutics for cancer management. Acta Biomaterialia, 2023, 155, 57-79.	4.1	8
734	Recombinant Interferon-Î² in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives. Cancers, 2022, 14, 5495.	1.7	4
735	cGAS-STING Pathway as the Target of Immunotherapy for Lung Cancer. Current Cancer Drug Targets, 2023, 23, 354-362.	0.8	2
736	The molecular basis of immuno-radiotherapy. International Journal of Radiation Biology, 2023, 99, 715-736.	1.0	5
737	Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy. Nature Nanotechnology, 2022, 17, 1332-1341.	15.6	20
738	Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies. Journal of Controlled Release, 2023, 353, 423-433.	4.8	23
739	Association of neutrophil-lymphocyte ratio (NLR) with the anthracycline-based neoadjuvant chemotherapy (NAC) clinical response in locally advanced breast cancer (LABC) in young women. Bali Medical Journal, 2022, 11, 602-608.	0.1	2
740	Carbonic Anhydrase IX (CAIX) Expressing Hypoxic Micro-environment Hampers CD8+ Immune Cell Infiltrate in Breast Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2023, 31, 26-32.	0.6	4
741	Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects. Journal of Clinical Medicine, 2022, 11, 6997.	1.0	1
742	Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation. Cells, 2022, 11, 3826.	1.8	8
743	Anti-CD19 chimeric antigen receptor T-cell followed by interferonâ^'Î± therapy induces durable complete remission in donor cell-derived acute lymphoblastic leukemia: A case report. Frontiers in Oncology, 0, 12, .	1.3	0
744	Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy. Pharmaceutics, 2022, 14, 2710.	2.0	2
745	Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. Cancer Cell, 2022, 40, 1550-1565.e7.	7.7	39
746	HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs. PLoS ONE, 2022, 17, e0274704.	1.1	2
747	Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment. Expert Opinion on Therapeutic Targets, 2022, 26, 923-936.	1.5	6

#	Article	IF	Citations
748	Breast Cancer Vaccine Containing a Novel Toll-like Receptor 7 Agonist and an Aluminum Adjuvant Exerts Antitumor Effects. International Journal of Molecular Sciences, 2022, 23, 15130.	1.8	6
750	MLL3 loss drives metastasis by promoting a hybrid epithelialâ€“mesenchymal transition state. Nature Cell Biology, 2023, 25, 145-158.	4.6	16
751	Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. Frontiers in Immunology, 0, 13, .	2.2	4
752	Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects. Epigenomics, 2022, 14, 1449-1464.	1.0	2
754	Specialized functions and sexual dimorphism explain the functional diversity of the myeloid populations during glioma progression. Cell Reports, 2023, 42, 111971.	2.9	4
755	Mining TCGA Database for Genes with Prognostic Value in Breast Cancer. International Journal of Molecular Sciences, 2023, 24, 1622.	1.8	2
756	Bifunctional cancer cellâ€“based vaccine concomitantly drives direct tumor killing and antitumor immunity. Science Translational Medicine, 2023, 15, .	5.8	18
757	Interleukin-34 cancels anti-tumor immunity by PARP inhibitor. Journal of Gynecologic Oncology, 0, 34, .	1.0	1
758	A Biodegradable Antigen Nanocapsule Promotes Antiâ€Tumor Immunity via the cGASâ€STING Pathway. Advanced Functional Materials, 2023, 33, .	7.8	3
759	Acidâ€Ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer. Advanced Materials, 2023, 35, .	11.1	23
760	Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses. PLoS ONE, 2023, 18, e0280364.	1.1	2
761	Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer. Cellular and Molecular Life Sciences, 2023, 80, .	2.4	3
762	MHC-dressing on dendritic cells: Boosting anti-tumor immunity via unconventional tumor antigen presentation. Seminars in Immunology, 2023, 66, 101710.	2.7	5
763	Model for predicting age-dependent safety and immunomodulatory effects of STING ligands in non-human primates. Molecular Therapy - Methods and Clinical Development, 2023, 28, 99-115.	1.8	1
764	RIG-Iâ€“like Receptor Regulation of Immune Cell Function and Therapeutic Implications. Journal of Immunology, 2022, 209, 845-854.	0.4	4
765	Immunogenic Cell Death in Cancer. , 2023, , .		0
766	Transcriptomic Analyses of Pretreatment Tumor Biopsy Samples, Response to Neoadjuvant Chemoradiotherapy, and Survival in Patients With Advanced Rectal Cancer. JAMA Network Open, 2023, 6, e2252140.	2.8	8
767	Reversing the NK inhibitory tumor microenvironment by targeting suppressive immune effectors. , 2023, , 27-63.		1

#	Article	IF	Citations
768	Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma. Journal of Gastroenterology, 2023, 58, 277-291.	2.3	6
769	Chemotherapy to potentiate the radiation-induced immune response. International Review of Cell and Molecular Biology, 2023, , 143-173.	1.6	1
770	Highlights into historical and current immune interventions for cancer. International Immunopharmacology, 2023, 117, 109882.	1.7	2
771	Virusâ€Like Particleâ€Induced cGASâ€STING Activation and AIM2 Inflammasomeâ€Mediated Pyroptosis for Robust Cancer Immunotherapy. Angewandte Chemie - International Edition, 2023, 62, .	7.2	5
772	Oncolytic Rodent Protoparvoviruses Evade a TLR- and RLR-Independent Antiviral Response in Transformed Cells. Pathogens, 2023, 12, 607.	1.2	2
773	Type 1 interferon mediated signaling is indispensable for eliciting anti-tumor responses by Mycobacterium indicus pranii. Frontiers in Immunology, 0, 14, .	2.2	0
774	Mechanism of SUMOylation-Mediated Regulation of Type I IFN Expression. Journal of Molecular Biology, 2023, 435, 167968.	2.0	6
775	IL-6/ERK signaling pathway participates in type I IFN-programmed, unconventional M2-like macrophage polarization. Scientific Reports, 2023, 13, .	1.6	6
776	After virus exposure, early bystander naÃ¯ve CD8 T cell activation relies on NAD+ salvage metabolism. Frontiers in Immunology, 0, 13, .	2.2	0
777	Exploiting RIG-I-like receptor pathway for cancer immunotherapy. Journal of Hematology and Oncology, 2023, 16, .	6.9	22
778	Clinical Significance of Tumour-Infiltrating B Lymphocytes (TIL-Bs) in Breast Cancer: A Systematic Literature Review. Cancers, 2023, 15, 1164.	1.7	4
779	How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles. Cancers, 2023, 15, 1324.	1.7	1
780	Expression profile of the microenvironment of morphological structures in luminal breast cancer. Genes and Cells, 2022, 17, 31-37.	0.2	0
781	Radiationâ€Induced Immunogenic Cell Death for Cancer Radioimmunotherapy. Small Methods, 2023, 7, .	4.6	14
782	Specific activation of cGAS-STING pathway by nanotherapeutics-mediated ferroptosis evoked endogenous signaling for boosting systemic tumor immunotherapy. Science Bulletin, 2023, 68, 622-636.	4.3	20
784	Immunomodulatory activity of manganese dioxide nanoparticles: Promising for novel vaccines and immunotherapeutics. Frontiers in Immunology, 0, 14, .	2.2	5
785	cGAS-dependent proinflammatory and immune homeostatic effects of the microtubule-targeting agent paclitaxel. Frontiers in Immunology, 0, 14, .	2.2	2
786	Role of Defensins in Tumor Biology. International Journal of Molecular Sciences, 2023, 24, 5268.	1.8	8

#	Article	IF	Citations
787	Phenotypes and Functions of Human Dendritic Cell Subsets in the Tumor Microenvironment. Methods in Molecular Biology, 2023, , 17-35.	0.4	3
791	Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis. Nature Communications, 2023, 14, .	5.8	6
793	Cancer immunotherapy: TÂcells and neutrophils working together to attack cancers. Cell, 2023, 186, 1304-1306.	13.5	3
794	Phospholipase A and acyltransferase 4/retinoic acid receptor responder 3 at the intersection of tumor suppression and pathogen restriction. Frontiers in Immunology, 0, 14, .	2.2	0
795	Biomaterial-enabled therapeutic modulation of cGAS-STING signaling for enhancing antitumor immunity. Molecular Therapy, 2023, 31, 1938-1959.	3.7	2
796	Dendritic cell-based immunotherapy: a potential player in oral cancer therapeutics. Immunotherapy, 2023, 15, 457-469.	1.0	4
797	MYC activation impairs cell-intrinsic IFNÎ³ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer. Cell Reports Medicine, 2023, 4, 101006.	3.3	3
798	Virusâ€Like Particleâ€Induced cGASâ€STING Activation and AIM2 Inflammasomeâ€Mediated Pyroptosis for Robust Cancer Immunotherapy. Angewandte Chemie, 2023, 135, .	1.6	2
811	Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics. British Journal of Cancer, 2023, 129, 24-37.	2.9	7
836	Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	34
856	Systemic Oncospheres: Host Inflammation and Cancer. , 2023, , 469-495.		0
857	Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer. International Review of Cell and Molecular Biology, 2024, , 145-179.	1.6	0
858	Cancer stem cell immunoediting by IFNÎ³. Cell Death and Disease, 2023, 14, .	2.7	0
868	Immunometabolism of dendritic cells in health and disease. Advances in Immunology, 2023, , .	1.1	0
895	Recent Advances of RNA m6A Modifications in Cancer Immunoediting and Immunotherapy. Cancer Treatment and Research, 2023, , 49-94.	0.2	0